Advanced Search
Disease Phase
Title Drug
Clinical Trials Listing
  • < Previous
  • 1
  • Next >
  • Penn Treatment Trials (15)
  • Penn Non-Treatment Trials (6)
  • Phase 1: Solid Tumor Trials (3)
  • Proton Therapy Trials (3)
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
CALGB-30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide III Radiotherapy Not Applicable
ECOG-E1505 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4cm)-IIIA Non-Small Lung Cancer (NSCLC) III Angiogenesis Inhibitor, Chemotherapy docetaxel; pemetrexed; carboplatin; cisplatin; gemcitabine; vinorelbine; bevacizumab; paclitaxel
SWOG-S0819 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) III Angiogenesis Inhibitor, Chemotherapy carboplatin; bevacizumab; cetuximab; paclitaxel
MO22097 An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First (1st)-Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy III Angiogenesis Inhibitor bevacizumab
OAM4971g A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease III Immunotherapy (Monoclonal Antibody), EGFR Inhibitor erlotinib; onartuzumab
PX-866-002 Phase 1/2 Study of PX-866 and Docetaxel in Patients With Solid Tumors II Chemotherapy, Signal Transduction Inhibitor docetaxel; PX-866
UPCC 18512 Phase 2 Study of Etirinotecan Pegol (NKTR-102) in the Treatment of Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of 2nd Line Treatment II Chemotherapy NKTR-102
ECOG-E3508 A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab With or Without IMC-A12 in Patients With Advanced Non-Squamous Non- Small Cell Lung Cancer II Biological Therapy, Chemotherapy, Signal Transduction Inhibitor carboplatin; bevacizumab; paclitaxel; cixutumumab
UPCC 27312 A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer II Radiotherapy, Signal Transduction Inhibitor veliparib
CDR0000736704 Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer I / II Chemotherapy, Signal Transduction Inhibitor cisplatin; etoposide; veliparib
AP26113-11-101 A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113 I / II Signal Transduction Inhibitor AP26113
UPCC 25508 Feasibility and PhaseI/II Trial of Preoperative Proton Beam Radiotherapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus NSCLC I / II Chemotherapy, Proton Therapy cisplatin; etoposide
UPCC 01510 Phase I Dose Escalation Trial of Proton Beam Radiotherapy With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III NSCLC I Chemotherapy, Proton Therapy carboplatin; cisplatin; etoposide; paclitaxel; nelfinavir mesylate
P07990 Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma I Signal Transduction Inhibitor MK-3475 (Immunotherapy : PD-1 inhibitor)
CA186-011 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors I Immunotherapy BMS-663513
Displaying: 1 - 15 of 15 Results
  • < Previous
  • 1
  • Next >